Published in Biomaterials on January 14, 2012
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano (2014) 0.91
CD44v6 Monoclonal Antibody-Conjugated Gold Nanostars for Targeted Photoacoustic Imaging and Plasmonic Photothermal Therapy of Gastric Cancer Stem-like Cells. Theranostics (2015) 0.91
Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev (2013) 0.89
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine (2013) 0.84
5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One (2012) 0.83
Targeting cancer stem cells by using the nanoparticles. Int J Nanomedicine (2015) 0.79
Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer. PLoS One (2014) 0.79
Photothermal therapy of glioblastoma multiforme using multiwalled carbon nanotubes optimized for diffusion in extracellular space. ACS Biomater Sci Eng (2016) 0.77
Targeting Cancer Stem Cells with Nanoparticle-Enabled Therapies. J Mol Biomark Diagn (2012) 0.77
Triple Negative Breast Cancer: Nanosolutions for a Big Challenge. Adv Sci (Weinh) (2015) 0.76
Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. J Inorg Biochem (2016) 0.76
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells. Front Pharmacol (2016) 0.76
Influence of carbon nanotubes and graphene nanosheets on photothermal effect of hydroxyapatite. J Colloid Interface Sci (2016) 0.76
Hyperthermia using nanoparticles - Promises and pitfalls. Int J Hyperthermia (2016) 0.75
Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. Oncotarget (2016) 0.75
Evaluation of multiwalled carbon nanotube cytotoxicity in cultures of human brain microvascular endothelial cells grown on plastic or basement membrane. Toxicol In Vitro (2017) 0.75
Cancer stem cells (CSCs), cervical CSCs and targeted therapies. Oncotarget (2017) 0.75
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy. Front Pharmacol (2017) 0.75
The use of nanoparticulates to treat breast cancer. Nanomedicine (Lond) (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A (2003) 12.17
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
A clearer vision for in vivo imaging. Nat Biotechnol (2001) 10.49
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A (2005) 7.70
Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett (2004) 7.12
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A (2004) 5.32
Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 4.41
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett (2010) 3.59
Carbon nanotubes: synthesis, integration, and properties. Acc Chem Res (2002) 3.32
Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett (2008) 3.20
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 2.33
Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med (2007) 2.29
Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst (2006) 2.10
Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia (2008) 1.60
Mechanisms of focal heat destruction of liver tumors. J Surg Res (2005) 1.45
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med (2010) 1.43
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol (2010) 1.36
Thermally induced injury and heat-shock protein expression in cells and tissues. Ann N Y Acad Sci (2005) 1.35
Nanoparticles for thermal cancer therapy. J Biomech Eng (2009) 1.28
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Triple-negative breast cancer. Curr Opin Oncol (2008) 1.07
Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol (1997) 1.04
Heat shock proteins and biological response to hyperthermia. Br J Cancer Suppl (1982) 1.00
Controlled nanometric phase transitions of phospholipid membranes by plasmonic heating of single gold nanoparticles. Nano Lett (2009) 0.99
Effects of hyperthermia on dividing Chinese hamster ovary cells and on microtubules in vitro. Cancer Res (1982) 0.97
The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells. Nanotechnology (2011) 0.95
Effects of hyperthermia in a malignant tumor. Cancer (1980) 0.94
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Physiological mechanisms in hyperthermia: a review. Int J Radiat Oncol Biol Phys (1984) 0.90
Nitric oxide-mediated inhibition of NFkappaB regulates hyperthermia-induced apoptosis. J Cell Biochem (2009) 0.86
Multi-scale heat and mass transfer modelling of cell and tissue cryopreservation. Philos Trans A Math Phys Eng Sci (2010) 0.85
Investigation of an optical limiting mechanism in multiwalled carbon nanotubes. Appl Opt (2000) 0.81
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med (2008) 4.63
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med (2008) 4.61
Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke (2004) 4.56
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med (2011) 4.34
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Estimating treatment effects using observational data. JAMA (2007) 4.12
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation (2005) 4.08
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet (2002) 4.07
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation (2007) 3.99
Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care (2002) 3.96
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Miniaturized gas ionization sensors using carbon nanotubes. Nature (2003) 3.83
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care (2006) 3.67
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
Long-term trends in the incidence of heart failure after myocardial infarction. Circulation (2008) 3.52
Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension (2004) 3.51
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2006) 3.48
Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation (2006) 3.41
Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab (2010) 3.39
Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care (2008) 3.33
C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med (2005) 3.31
Regulation of ferritin genes and protein. Blood (2002) 3.27
C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 3.25
Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol (2012) 3.24
Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23
The influence of gender and age on disability following ischemic stroke: the Framingham study. J Stroke Cerebrovasc Dis (2007) 3.22
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke (2004) 3.13
The randomized registry trial--the next disruptive technology in clinical research? N Engl J Med (2013) 3.13
Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med (2010) 3.05
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med (2005) 2.89
Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol (2004) 2.89
Dietary glycemic index and glycemic load, carbohydrate and fiber intake, and measures of insulin sensitivity, secretion, and adiposity in the Insulin Resistance Atherosclerosis Study. Diabetes Care (2005) 2.86
Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke (2008) 2.84
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res (2004) 2.75
Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med (2004) 2.74
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology (2008) 2.70
Large scale growth and characterization of atomic hexagonal boron nitride layers. Nano Lett (2010) 2.66
Large-area vapor-phase growth and characterization of MoS(2) atomic layers on a SiO(2) substrate. Small (2012) 2.66
Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol (2008) 2.64
Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.63
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry (2010) 2.57
Atomic layers of hybridized boron nitride and graphene domains. Nat Mater (2010) 2.57
Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet (2007) 2.51
Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol (2006) 2.46
Framingham stroke risk profile and lowered cognitive performance. Stroke (2004) 2.46
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) (2010) 2.42